"Pol\u00EDvka, Ji\u0159\u00ED" . "4"^^ . "Anaplastick\u00E9 oligodendrogliomy - nade\u0161el \u010Das pro personalizovanou medic\u00EDnu?" . "Anaplastick\u00E9 oligodendrogliomy - nade\u0161el \u010Das pro personalizovanou medic\u00EDnu?" . . . "P(ED2.1.00/03.0076)" . . . "1210-7859" . "\u010Cesk\u00E1 a slovensk\u00E1 neurologie a neurochirurgie" . "Oligodendrogliomy pat\u0159\u00ED k vz\u00E1cn\u00FDm, av\u0161ak nejl\u00E9pe prozkouman\u00FDm n\u00E1dor\u016Fm v neuroonkologii. Ji\u017E dlouho je zn\u00E1ma jejich v\u011Bt\u0161\u00ED senzitivita na radioterapii a chemoterapii ve srovn\u00E1n\u00ED s ostatn\u00EDmi gliomy. Specifick\u00FDm n\u00E1lezem je \u010Dast\u00E1 p\u0159\u00EDtomnost chromozom\u00E1ln\u00ED kodelece 1p/ 19q. Teprve v\u00FDsledky dlouhodob\u00E9ho sledov\u00E1n\u00ED nemocn\u00FDch ve dvou z\u00E1sadn\u00EDch klinick\u00FDch studi\u00EDch f\u00E1ze III - RTOG 9402 a EORTC 26951 prok\u00E1zaly p\u0159\u00EDzniv\u00FD \u00FA\u010Dinek kombinovan\u00E9 onkologick\u00E9 l\u00E9\u010Dby radioterapie a chemoterapie v kombinaci prokarbazin, lomustin-CCNU a vinkristin (PCV) u nemocn\u00FDch s anaplastick\u00FDm oligodendrogliomem a anaplastick\u00FDm oligoastrocytomem s 1p/ 19q kodelec\u00ED. P\u0159\u00EDtomnost kodelece 1p/ 19q je d\u016Fle\u017Eit\u00FDm dia gnostick\u00FDm, pozitivn\u00EDm prognostick\u00FDm a siln\u00FDm prediktivn\u00EDm bio markerem oligodendrogliom\u016F. Diskutuje se o dal\u0161\u00EDch molekul\u00E1rn\u011B genetick\u00FDch charakteristik\u00E1ch oligodendrogliom\u016F - mutaci metabolick\u00E9ho enzymu Izocitr\u00E1t dehydrogen\u00E1zy 1 a 2 (IDH 1/ 2), metylaci promotoru genu pro O- 6- metylguanin-metyltransfer\u00E1zu (MGMT), hypermetyla\u010Dn\u00EDm stavu ostr\u016Fvk\u016F cytozin-guanin n\u00E1dorov\u00E9ho genomu (G- CIMP) a mo\u017Enosti l\u00E9\u010Dby t\u011Bchto n\u00E1dor\u016F. Uvedeny jsou aktu\u00E1ln\u00ED poznatky optim\u00E1ln\u00EDho managementu anaplastick\u00FDch oligodendrogliom\u016F respektuj\u00EDc\u00ED z\u00E1sady personalizovan\u00E9 medic\u00EDny."@cs . . . "3242" . "Oligodendrogliomy pat\u0159\u00ED k vz\u00E1cn\u00FDm, av\u0161ak nejl\u00E9pe prozkouman\u00FDm n\u00E1dor\u016Fm v neuroonkologii. Ji\u017E dlouho je zn\u00E1ma jejich v\u011Bt\u0161\u00ED senzitivita na radioterapii a chemoterapii ve srovn\u00E1n\u00ED s ostatn\u00EDmi gliomy. Specifick\u00FDm n\u00E1lezem je \u010Dast\u00E1 p\u0159\u00EDtomnost chromozom\u00E1ln\u00ED kodelece 1p/ 19q. Teprve v\u00FDsledky dlouhodob\u00E9ho sledov\u00E1n\u00ED nemocn\u00FDch ve dvou z\u00E1sadn\u00EDch klinick\u00FDch studi\u00EDch f\u00E1ze III - RTOG 9402 a EORTC 26951 prok\u00E1zaly p\u0159\u00EDzniv\u00FD \u00FA\u010Dinek kombinovan\u00E9 onkologick\u00E9 l\u00E9\u010Dby radioterapie a chemoterapie v kombinaci prokarbazin, lomustin-CCNU a vinkristin (PCV) u nemocn\u00FDch s anaplastick\u00FDm oligodendrogliomem a anaplastick\u00FDm oligoastrocytomem s 1p/ 19q kodelec\u00ED. P\u0159\u00EDtomnost kodelece 1p/ 19q je d\u016Fle\u017Eit\u00FDm dia gnostick\u00FDm, pozitivn\u00EDm prognostick\u00FDm a siln\u00FDm prediktivn\u00EDm bio markerem oligodendrogliom\u016F. Diskutuje se o dal\u0161\u00EDch molekul\u00E1rn\u011B genetick\u00FDch charakteristik\u00E1ch oligodendrogliom\u016F - mutaci metabolick\u00E9ho enzymu Izocitr\u00E1t dehydrogen\u00E1zy 1 a 2 (IDH 1/ 2), metylaci promotoru genu pro O- 6- metylguanin-metyltransfer\u00E1zu (MGMT), hypermetyla\u010Dn\u00EDm stavu ostr\u016Fvk\u016F cytozin-guanin n\u00E1dorov\u00E9ho genomu (G- CIMP) a mo\u017Enosti l\u00E9\u010Dby t\u011Bchto n\u00E1dor\u016F. Uvedeny jsou aktu\u00E1ln\u00ED poznatky optim\u00E1ln\u00EDho managementu anaplastick\u00FDch oligodendrogliom\u016F respektuj\u00EDc\u00ED z\u00E1sady personalizovan\u00E9 medic\u00EDny." . . "P\u0159ib\u00E1\u0148, Vladim\u00EDr" . "Anaplastic Oligodendrogliomas - the Age of Personalized Medicine Has Arrived?"@en . "000339709800004" . "personalized medicine; biomarkers; chromosome deletion; anaplastic oligodendroglioma"@en . . . "Anaplastick\u00E9 oligodendrogliomy - nade\u0161el \u010Das pro personalizovanou medic\u00EDnu?"@cs . . "7"^^ . "http://www.csnn.eu/ceska-slovenska-neurologie-clanek/anaplasticke-oligodendrogliomy-nadesel-cas-pro-personalizovanou-medicinu-49298" . . . "4" . . "Anaplastic Oligodendrogliomas - the Age of Personalized Medicine Has Arrived?"@en . "RIV/00216208:11140/14:10227352" . . . "CZ - \u010Cesk\u00E1 republika" . "77" . "RIV/00216208:11140/14:10227352!RIV15-MSM-11140___" . "11140" . "Rohan, Vladim\u00EDr" . . "Anaplastick\u00E9 oligodendrogliomy - nade\u0161el \u010Das pro personalizovanou medic\u00EDnu?"@cs . "Oligodendrogliomas are uncommon but extensively investigated tumours in neurooncology. Their superior sensitivity to radiotherapy and chemotherapy compared to other gliomas has long been known. Chromosomal codeletion 1p/19q is frequent in this tumour type. A longterm follow up of two landmark phase III trials - RTOG 9402 and EORTC 26951 has shown a favourable effect of combined radiotherapy and chemotherapy - procarbazine, lomustine (CCNU), vincristine - in patients with anaplastic oligodendrogliomas and anaplastic oligoastrocytomas carrying the codeletion 1p/19q. This codeletion serves as an important diagnostic, positive prognostic and strong predictive biomarker. The role of the other molecular biomarkers (isocitrate dehydrogenase - IDH1, IDH2 mutations, methylation of the MGMT promoter, glioma cytosine - guanine islands methylator phenotype - G-CIMP) in oligodendroglial tumours is also discussed. All these data facilitate the new personalised approach to the management and treatment of anaplastic oligodendroglial tumours."@en . . "4"^^ . . . "[560F2C52FEE4]" .